S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
All the trading advice you’ve ever received boils down to this (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
All the trading advice you’ve ever received boils down to this (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
All the trading advice you’ve ever received boils down to this (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
All the trading advice you’ve ever received boils down to this (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections

Faron Pharmaceuticals Oy Share Price, News & Analysis (LON:FARN)

GBX 274
+14.00 (+5.38%)
(As of 12/1/2023 ET)
Compare
Today's Range
250
274
50-Day Range
251
350
52-Week Range
218.86
395
Volume
20,699 shs
Average Volume
9,510 shs
Market Capitalization
£188.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

FARN stock logo

About Faron Pharmaceuticals Oy Stock (LON:FARN)

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. It also develops Haematokine, an investigational AOC3 inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. In addition, the company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

FARN Stock Price History

FARN Stock News Headlines

Faron Pharmaceuticals Oy FARN
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Faron Pharma raises €7.1m as cancer study continues apace
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Faron Pharma data 'extremely encouraging', says CEO
Faron Pharmaceuticals data 'highly encouraging', say bank
Faron Pharmaceuticals Ltd Results of the Extraordinary General Meeting
Faron Pharmaceuticals Announces Board Changes
Faron Pharma appoints new chief medical officer
See More Headlines
Receive FARN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Faron Pharmaceuticals Oy and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

Net Income
£-29,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£-725,000.00
Cash Flow
GBX 13.70 per share
Book Value
GBX (14) per share

Miscellaneous

Free Float
N/A
Market Cap
£188.48 million
Optionable
Not Optionable
Beta
-0.06
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Juho Markku Jalkanen M.D. (Age 45)
    MSc, Ph.D., Chief Operating Officer
    Comp: $554.15k
  • Dr. Markku Tapani Jalkanen Ph.D. (Age 69)
    Founder, CEO & Executive Director
    Comp: $245.38k
  • Mr. James M. O'Brien CPA
    M.B.A., Chief Financial Officer
  • Dr. Maija Hollmen Ph.D.
    Chief Scientific Officer
  • Mr. Vesa Karvonen L.L.M. (Age 51)
    General Counsel
  • Ms. Jennifer Smith-Parker
    Head of Communications
  • Mr. Juuso Vakkuri M.A.
    M.B.A., M.Sc., Chief Human Resources Officer
  • Dr. Juhana Heinonen
    Chief Commercial Officer
  • Dr. Birge Berns M.D.
    Interim Chief Medical Officer














FARN Stock Analysis - Frequently Asked Questions

How have FARN shares performed in 2023?

Faron Pharmaceuticals Oy's stock was trading at GBX 300 at the beginning of 2023. Since then, FARN stock has decreased by 8.7% and is now trading at GBX 274.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Faron Pharmaceuticals Oy own?
How do I buy shares of Faron Pharmaceuticals Oy?

Shares of FARN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:FARN) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -